Top of page
Global Site Navigation

News and events

Local Section Navigation
You are here: Main Content

Weight loss for prostate cancer patients

Monday, 27 May 2019


Hormone blocking therapy, such as Zoladex or Lucrin, is a common treatment for prostate cancer. One of the many side effects this treatment may induce is weight gain. Healthy lifestyle changes of increased exercise and improved nutrition have been shown to be safe and well tolerated within the prostate cancer population resulting in improved physical function and quality of life. The purpose of this study is to assess the effectiveness of an exercise and nutrition programme designed to induce weight loss in prostate cancer patients.

The study will include a 6-week waiting period, followed by a 3-month supervised exercise and nutrition intervention, and a further 3-month home-based programme. The participant will attend a number of testing sessions during this time which will include assessment of body composition (fat, muscle, and bone mass), resting metabolic rate (body's energy usage), blood and inflammatory markers, physical function (muscular strength, aerobic fitness), nutrition intake, and quality of life.

The 3-month supervised exercise and nutrition intervention will involve 3 supervised exercise sessions a week for 12 weeks as well as 3 nutritional counselling sessions during this time. Sessions may be completed either at Edith Cowan University’s Mount Lawley or Joondalup campuses. The exercise will involve individually prescribed supervised resistance training and home-based aerobic training accumulating 300 minutes/week (45 minutes/day). The nutrition component will also be individually prescribed and focus on decreasing portion sizes and advise on carbohydrate, fat, and protein intake.

Ethics approval has been granted by Edith Cowan University Human Research Ethics Committee.  You may be eligible for this study if you:

  • Are currently receiving hormone blocking therapy for more than 6 months as part of your prostate cancer treatment plan;
  • Have no bone metastasis (cancer spread to the bones)
  • Have no medical conditions that may prevent you completing an exercise or nutrition programme.
For more details, please contact the Exercise Medicine Research Institute on 6304 3444 or email


Skip to top of page